Skip to main content
Top
Published in: BMC Geriatrics 1/2021

Open Access 01-12-2021 | Addiction | Research article

General practitioners’ deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries

Authors: Katharina Tabea Jungo, Sophie Mantelli, Zsofia Rozsnyai, Aristea Missiou, Biljana Gerasimovska Kitanovska, Birgitta Weltermann, Christian Mallen, Claire Collins, Daiana Bonfim, Donata Kurpas, Ferdinando Petrazzuoli, Gindrovel Dumitra, Hans Thulesius, Heidrun Lingner, Kasper Lorenz Johansen, Katharine Wallis, Kathryn Hoffmann, Lieve Peremans, Liina Pilv, Marija Petek Šter, Markus Bleckwenn, Martin Sattler, Milly van der Ploeg, Péter Torzsa, Petra Bomberová Kánská, Shlomo Vinker, Radost Assenova, Raquel Gomez Bravo, Rita P. A. Viegas, Rosy Tsopra, Sanda Kreitmayer Pestic, Sandra Gintere, Tuomas H. Koskela, Vanja Lazic, Victoria Tkachenko, Emily Reeve, Clare Luymes, Rosalinde K. E. Poortvliet, Nicolas Rodondi, Jacobijn Gussekloo, Sven Streit

Published in: BMC Geriatrics | Issue 1/2021

Login to get access

Abstract

Background

General practitioners (GPs) should regularly review patients’ medications and, if necessary, deprescribe, as inappropriate polypharmacy may harm patients’ health. However, deprescribing can be challenging for physicians. This study investigates GPs’ deprescribing decisions in 31 countries.

Methods

In this case vignette study, GPs were invited to participate in an online survey containing three clinical cases of oldest-old multimorbid patients with potentially inappropriate polypharmacy. Patients differed in terms of dependency in activities of daily living (ADL) and were presented with and without history of cardiovascular disease (CVD). For each case, we asked GPs if they would deprescribe in their usual practice. We calculated proportions of GPs who reported they would deprescribe and performed a multilevel logistic regression to examine the association between history of CVD and level of dependency on GPs’ deprescribing decisions.

Results

Of 3,175 invited GPs, 54% responded (N = 1,706). The mean age was 50 years and 60% of respondents were female. Despite differences across GP characteristics, such as age (with older GPs being more likely to take deprescribing decisions), and across countries, overall more than 80% of GPs reported they would deprescribe the dosage of at least one medication in oldest-old patients (> 80 years) with polypharmacy irrespective of history of CVD. The odds of deprescribing was higher in patients with a higher level of dependency in ADL (OR =1.5, 95%CI 1.25 to 1.80) and absence of CVD (OR =3.04, 95%CI 2.58 to 3.57).

Interpretation

The majority of GPs in this study were willing to deprescribe one or more medications in oldest-old multimorbid patients with polypharmacy. Willingness was higher in patients with increased dependency in ADL and lower in patients with CVD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–98.PubMedPubMedCentralCrossRef Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–98.PubMedPubMedCentralCrossRef
2.
go back to reference Herr M, Grondin H, Sanchez S, Armaingaud D, Blochet C, Vial A, et al. Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France. Eur J Clin Pharmacol. 2017;73(5):601–8.PubMedCrossRef Herr M, Grondin H, Sanchez S, Armaingaud D, Blochet C, Vial A, et al. Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France. Eur J Clin Pharmacol. 2017;73(5):601–8.PubMedCrossRef
3.
go back to reference Abdulah R, Insani WN, Barliana MI. Polypharmacy leads to increased prevalence of potentially inappropriate medication in the Indonesian geriatric population visiting primary care facilities. Ther Clin Risk Manag. 2018;2018(14):1591–7.CrossRef Abdulah R, Insani WN, Barliana MI. Polypharmacy leads to increased prevalence of potentially inappropriate medication in the Indonesian geriatric population visiting primary care facilities. Ther Clin Risk Manag. 2018;2018(14):1591–7.CrossRef
4.
go back to reference Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):154.PubMedPubMedCentralCrossRef Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):154.PubMedPubMedCentralCrossRef
5.
go back to reference Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.PubMedCrossRef Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.PubMedCrossRef
6.
go back to reference Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized PatientsPIMs defined by STOPP criteria and risk of ADEs. JAMA Intern Med. 2011;171(11):1013–9.CrossRef Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized PatientsPIMs defined by STOPP criteria and risk of ADEs. JAMA Intern Med. 2011;171(11):1013–9.CrossRef
7.
go back to reference Lindblad CI, Artz MB, Pieper CF, Sloane RJ, Hajjar ER, Ruby CM, et al. Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother. 2005;39(3):412–7.PubMedCrossRef Lindblad CI, Artz MB, Pieper CF, Sloane RJ, Hajjar ER, Ruby CM, et al. Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother. 2005;39(3):412–7.PubMedCrossRef
8.
go back to reference Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28(8):1133–43.PubMedCrossRef Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28(8):1133–43.PubMedCrossRef
9.
go back to reference Crentsil V, Ricks MO, Xue QL, Fried LP. A pharmacoepidemiologic study of community-dwelling, disabled older women: factors associated with medication use. Am J Geriatr Pharmacother. 2010;8(3):215–24.PubMedCrossRef Crentsil V, Ricks MO, Xue QL, Fried LP. A pharmacoepidemiologic study of community-dwelling, disabled older women: factors associated with medication use. Am J Geriatr Pharmacother. 2010;8(3):215–24.PubMedCrossRef
10.
go back to reference Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514–22.PubMedCrossRef Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514–22.PubMedCrossRef
11.
go back to reference Corsonello A, Pedone C, Lattanzio F, Lucchetti M, Garasto S, Di Muzio M, et al. Potentially inappropriate medications and functional decline in elderly hospitalized patients. J Am Geriatr Soc. 2009;57(6):1007–14.PubMedCrossRef Corsonello A, Pedone C, Lattanzio F, Lucchetti M, Garasto S, Di Muzio M, et al. Potentially inappropriate medications and functional decline in elderly hospitalized patients. J Am Geriatr Soc. 2009;57(6):1007–14.PubMedCrossRef
12.
go back to reference Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol A Biol Sci Med Sci. 2014;69(4):423–9.PubMedCrossRef Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol A Biol Sci Med Sci. 2014;69(4):423–9.PubMedCrossRef
13.
go back to reference Fletcher PC, Berg K, Dalby DM, Hirdes JP. Risk factors for falling among community-based seniors. J Patient Safety. 2009;5(2):61–6.CrossRef Fletcher PC, Berg K, Dalby DM, Hirdes JP. Risk factors for falling among community-based seniors. J Patient Safety. 2009;5(2):61–6.CrossRef
14.
go back to reference Masumoto S, Sato M, Maeno T, Ichinohe Y, Maeno T. Potentially inappropriate medications with polypharmacy increase the risk of falls in older Japanese patients: 1-year prospective cohort study. Geriatr Gerontol Int. 2018;18(7):1064–70.PubMedCrossRef Masumoto S, Sato M, Maeno T, Ichinohe Y, Maeno T. Potentially inappropriate medications with polypharmacy increase the risk of falls in older Japanese patients: 1-year prospective cohort study. Geriatr Gerontol Int. 2018;18(7):1064–70.PubMedCrossRef
15.
go back to reference Hyttinen V, Jyrkka J, Valtonen H. A systematic review of the impact of potentially inappropriate medication on health care utilization and costs among older adults. Med Care. 2016;54(10):950–64.PubMedCrossRef Hyttinen V, Jyrkka J, Valtonen H. A systematic review of the impact of potentially inappropriate medication on health care utilization and costs among older adults. Med Care. 2016;54(10):950–64.PubMedCrossRef
16.
go back to reference Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73(20):2584–95.PubMedPubMedCentralCrossRef Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73(20):2584–95.PubMedPubMedCentralCrossRef
17.
go back to reference Hilmer SN, Gnjidic D, Le Couteur DG. Thinking through the medication list - appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician. 2012;41(12):924–8.PubMed Hilmer SN, Gnjidic D, Le Couteur DG. Thinking through the medication list - appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician. 2012;41(12):924–8.PubMed
18.
go back to reference Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–68.PubMedCrossRef Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–68.PubMedCrossRef
19.
go back to reference Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate Polypharmacy: the process of DeprescribingReducing inappropriate PolypharmacyReducing inappropriate Polypharmacy. JAMA Intern Med. 2015;175(5):827–34.PubMedCrossRef Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate Polypharmacy: the process of DeprescribingReducing inappropriate PolypharmacyReducing inappropriate Polypharmacy. JAMA Intern Med. 2015;175(5):827–34.PubMedCrossRef
20.
go back to reference Frank C. Deprescribing: a new word to guide medication review. Can Med Assoc J. 2014;186(6):407–8.CrossRef Frank C. Deprescribing: a new word to guide medication review. Can Med Assoc J. 2014;186(6):407–8.CrossRef
21.
go back to reference Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging de fi nition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.PubMedPubMedCentralCrossRef Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging de fi nition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.PubMedPubMedCentralCrossRef
22.
go back to reference Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust. 2014;201(7):386–9.PubMedCrossRef Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust. 2014;201(7):386–9.PubMedCrossRef
23.
go back to reference Sibbald B. Reducing inappropriate prescribing easier said than done. Can Med Assoc J. 2017;189(19):E706–E7.CrossRef Sibbald B. Reducing inappropriate prescribing easier said than done. Can Med Assoc J. 2017;189(19):E706–E7.CrossRef
24.
go back to reference Cullinan S, Raae Hansen C, Byrne S, O'Mahony D, Kearney P, Sahm L. Challenges of deprescribing in the multimorbid patient. Eur J Hosp Pharm. 2017;24(1):43–6.PubMedPubMedCentralCrossRef Cullinan S, Raae Hansen C, Byrne S, O'Mahony D, Kearney P, Sahm L. Challenges of deprescribing in the multimorbid patient. Eur J Hosp Pharm. 2017;24(1):43–6.PubMedPubMedCentralCrossRef
25.
go back to reference Wallis KA, Andrews A, Henderson M. Swimming against the tide: primary care Physicians' views on Deprescribing in everyday practice. Ann Fam Med. 2017;15(4):341–6.PubMedPubMedCentralCrossRef Wallis KA, Andrews A, Henderson M. Swimming against the tide: primary care Physicians' views on Deprescribing in everyday practice. Ann Fam Med. 2017;15(4):341–6.PubMedPubMedCentralCrossRef
26.
go back to reference Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807.PubMedCrossRef Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807.PubMedCrossRef
27.
go back to reference Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. Br J Gen Pract. 2016;66(649):e552–60.PubMedPubMedCentralCrossRef Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. Br J Gen Pract. 2016;66(649):e552–60.PubMedPubMedCentralCrossRef
28.
go back to reference Mantelli S, Jungo KT, Rozsnyai Z, Reeve E, Luymes CH, Poortvliet RKE, et al. How general practitioners would deprescribe in frail oldest-old with polypharmacy - the LESS study. BMC Fam Pract. 2018;19(1):169.PubMedPubMedCentralCrossRef Mantelli S, Jungo KT, Rozsnyai Z, Reeve E, Luymes CH, Poortvliet RKE, et al. How general practitioners would deprescribe in frail oldest-old with polypharmacy - the LESS study. BMC Fam Pract. 2018;19(1):169.PubMedPubMedCentralCrossRef
29.
go back to reference Streit S, Verschoor M, Rodondi N, Bonfim D, Burman RA, Collins C, et al. Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries. BMC Geriatr. 2017;17(1):93.PubMedPubMedCentralCrossRef Streit S, Verschoor M, Rodondi N, Bonfim D, Burman RA, Collins C, et al. Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries. BMC Geriatr. 2017;17(1):93.PubMedPubMedCentralCrossRef
30.
go back to reference van der Ploeg MA, Streit S, Achterberg WP, Beers E, Bohnen AM, Burman RA, et al. Patient characteristics and general Practitioners’ advice to stop statins in oldest-old patients: a survey study across 30 countries. J Gen Intern Med. 2019;34(9):1751–7. van der Ploeg MA, Streit S, Achterberg WP, Beers E, Bohnen AM, Burman RA, et al. Patient characteristics and general Practitioners’ advice to stop statins in oldest-old patients: a survey study across 30 countries. J Gen Intern Med. 2019;34(9):1751–7.
31.
go back to reference Eysenbach G. Correction: improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res. 2012;14(1):e8.PubMedCentralCrossRef Eysenbach G. Correction: improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res. 2012;14(1):e8.PubMedCentralCrossRef
32.
go back to reference Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.PubMedPubMedCentralCrossRef Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.PubMedPubMedCentralCrossRef
33.
go back to reference Luymes CH, van der Kleij RM, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50(6):446–54.PubMedCrossRef Luymes CH, van der Kleij RM, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50(6):446–54.PubMedCrossRef
34.
go back to reference Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.PubMedPubMedCentralCrossRef Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.PubMedPubMedCentralCrossRef
35.
go back to reference Bolmsjo BB, Palagyi A, Keay L, Potter J, Lindley RI. Factors influencing deprescribing for residents in advanced care facilities: insights from general practitioners in Australia and Sweden. BMC Fam Pract. 2016;17(1):152.PubMedPubMedCentralCrossRef Bolmsjo BB, Palagyi A, Keay L, Potter J, Lindley RI. Factors influencing deprescribing for residents in advanced care facilities: insights from general practitioners in Australia and Sweden. BMC Fam Pract. 2016;17(1):152.PubMedPubMedCentralCrossRef
36.
go back to reference Anderson K, Foster M, Freeman C, Luetsch K, Scott I. Negotiating "Unmeasurable harm and benefit": perspectives of general practitioners and consultant pharmacists on Deprescribing in the primary care setting. Qual Health Res. 2017;27(13):1936–47.PubMedCrossRef Anderson K, Foster M, Freeman C, Luetsch K, Scott I. Negotiating "Unmeasurable harm and benefit": perspectives of general practitioners and consultant pharmacists on Deprescribing in the primary care setting. Qual Health Res. 2017;27(13):1936–47.PubMedCrossRef
37.
go back to reference Moen J, Norrgard S, Antonov K, Nilsson JL, Ring L. GPs' perceptions of multiple-medicine use in older patients. J Eval Clin Pract. 2010;16(1):69–75.PubMedCrossRef Moen J, Norrgard S, Antonov K, Nilsson JL, Ring L. GPs' perceptions of multiple-medicine use in older patients. J Eval Clin Pract. 2010;16(1):69–75.PubMedCrossRef
38.
go back to reference Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedPubMedCentralCrossRef Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedPubMedCentralCrossRef
39.
go back to reference Sinnott C, Hugh SM, Boyce MB, Bradley CP. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. Br J Gen Pract. 2015;65(632):e184–91.PubMedPubMedCentralCrossRef Sinnott C, Hugh SM, Boyce MB, Bradley CP. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. Br J Gen Pract. 2015;65(632):e184–91.PubMedPubMedCentralCrossRef
40.
go back to reference Ní Chróinín D, Ní Chróinín C, Beveridge A. Factors influencing deprescribing habits among geriatricians. Age Ageing. 2015;44(4):704–8.PubMedCrossRef Ní Chróinín D, Ní Chróinín C, Beveridge A. Factors influencing deprescribing habits among geriatricians. Age Ageing. 2015;44(4):704–8.PubMedCrossRef
41.
go back to reference Abbasi M, Rolfson D, Khera AS, Dabravolskaj J, Dent E, Xia L. Identification and management of frailty in the primary care setting. Can Med Assoc J. 2018;190(38):E1134–E40.CrossRef Abbasi M, Rolfson D, Khera AS, Dabravolskaj J, Dent E, Xia L. Identification and management of frailty in the primary care setting. Can Med Assoc J. 2018;190(38):E1134–E40.CrossRef
42.
go back to reference Davies BR, Baxter H, Rooney J, Simons P, Sephton A, Purdy S, et al. Frailty assessment in primary health care and its association with unplanned secondary care use: a rapid review. BJGP Open. 2018;2(1):bjgpopen18X101325.PubMedPubMedCentralCrossRef Davies BR, Baxter H, Rooney J, Simons P, Sephton A, Purdy S, et al. Frailty assessment in primary health care and its association with unplanned secondary care use: a rapid review. BJGP Open. 2018;2(1):bjgpopen18X101325.PubMedPubMedCentralCrossRef
43.
go back to reference Thompson W, Lundby C, Graabæk T, Nielsen DS, Ryg J, Søndergaard J, et al. Tools for Deprescribing in frail older persons and those with limited life expectancy: a systematic review. J Am Geriatr Soc. 2019;67(1):172–80.PubMedCrossRef Thompson W, Lundby C, Graabæk T, Nielsen DS, Ryg J, Søndergaard J, et al. Tools for Deprescribing in frail older persons and those with limited life expectancy: a systematic review. J Am Geriatr Soc. 2019;67(1):172–80.PubMedCrossRef
44.
go back to reference Goyal P, Anderson TS, Bernacki GM, Marcum ZA, Orkaby AR, Kim D, et al. Physician perspectives on Deprescribing cardiovascular medications for older adults. J Am Geriatr Soc. 2020;68(1):78–86.PubMedCrossRef Goyal P, Anderson TS, Bernacki GM, Marcum ZA, Orkaby AR, Kim D, et al. Physician perspectives on Deprescribing cardiovascular medications for older adults. J Am Geriatr Soc. 2020;68(1):78–86.PubMedCrossRef
45.
go back to reference By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94.
46.
go back to reference McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28.PubMedPubMedCentralCrossRef McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28.PubMedPubMedCentralCrossRef
47.
go back to reference Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.PubMedCrossRef Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.PubMedCrossRef
48.
go back to reference Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.PubMedPubMedCentralCrossRef Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.PubMedPubMedCentralCrossRef
49.
go back to reference Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evid Based Clin Pract Guideline. 2017;63(5):354–64. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evid Based Clin Pract Guideline. 2017;63(5):354–64.
50.
go back to reference Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174–9.PubMedCrossRef Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174–9.PubMedCrossRef
51.
go back to reference Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons. Evid Based Clin Pract Guideline. 2017;63(11):832–43. Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons. Evid Based Clin Pract Guideline. 2017;63(11):832–43.
52.
go back to reference Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Canadian Fam Phys Medecin de famille canadien. 2018;64(1):17–27. Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Canadian Fam Phys Medecin de famille canadien. 2018;64(1):17–27.
53.
go back to reference Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Canadian Fam Phys Medecin de famille canadien. 2018;64(5):339–51. Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Canadian Fam Phys Medecin de famille canadien. 2018;64(5):339–51.
Metadata
Title
General practitioners’ deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries
Authors
Katharina Tabea Jungo
Sophie Mantelli
Zsofia Rozsnyai
Aristea Missiou
Biljana Gerasimovska Kitanovska
Birgitta Weltermann
Christian Mallen
Claire Collins
Daiana Bonfim
Donata Kurpas
Ferdinando Petrazzuoli
Gindrovel Dumitra
Hans Thulesius
Heidrun Lingner
Kasper Lorenz Johansen
Katharine Wallis
Kathryn Hoffmann
Lieve Peremans
Liina Pilv
Marija Petek Šter
Markus Bleckwenn
Martin Sattler
Milly van der Ploeg
Péter Torzsa
Petra Bomberová Kánská
Shlomo Vinker
Radost Assenova
Raquel Gomez Bravo
Rita P. A. Viegas
Rosy Tsopra
Sanda Kreitmayer Pestic
Sandra Gintere
Tuomas H. Koskela
Vanja Lazic
Victoria Tkachenko
Emily Reeve
Clare Luymes
Rosalinde K. E. Poortvliet
Nicolas Rodondi
Jacobijn Gussekloo
Sven Streit
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-020-01953-6

Other articles of this Issue 1/2021

BMC Geriatrics 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.